Egidi, M. J., Krug, S., Haybäck, J., Michl, P., & Griesmann, H. (2023). Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis. British journal of cancer, 129(8), . https://doi.org/10.1038/s41416-023-02389-6
Chicago-Zitierstil (17. Ausg.)Egidi, Maren Juliane, Sebastian Krug, Johannes Haybäck, Patrick Michl, und Heidi Griesmann. "Anti-angiogenic Therapy Using the Multi-tyrosine Kinase Inhibitor Regorafenib Enhances Tumor Progression in a Transgenic Mouse Model of ß-cell Carcinogenesis." British Journal of Cancer 129, no. 8 (2023). https://doi.org/10.1038/s41416-023-02389-6.
MLA-Zitierstil (9. Ausg.)Egidi, Maren Juliane, et al. "Anti-angiogenic Therapy Using the Multi-tyrosine Kinase Inhibitor Regorafenib Enhances Tumor Progression in a Transgenic Mouse Model of ß-cell Carcinogenesis." British Journal of Cancer, vol. 129, no. 8, 2023, https://doi.org/10.1038/s41416-023-02389-6.